Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
3 December 2020Portfolio NewsMerck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors
- 23 November 2020Portfolio NewsThe Boston Globe Names Deciphera a Top Place to Work for 2020
- 18 November 2020Portfolio NewsPionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
- 18 November 2020Portfolio NewsSutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
17 November 2020Portfolio NewsAVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
10 November 2020Portfolio NewsXilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10 November 2020SV NewsKate Bingham writes the foreword for Movers and Shakers in BioBusiness 2020
29 September 2020Portfolio NewsAlchemab partners with Amii to accelerate the development of novel therapeutics to cure disease- 28 September 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
- 18 September 2020SV NewsSV Health Investors welcomes six new Venture Partners to the Biotech team
- 15 September 2020Portfolio NewsSV Health Investors announces launch of biotech portfolio company, Cellinta and the Company’s appointment of Dr Soraya Bekkali as CEO
